EGFR T790M Recruiting Phase 2 Trials for Osimertinib (DB09330)

IndicationStatusPhase
DBCOND0025017 (EGFR T790M)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03810066Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)Treatment